Close Menu

Breaking News

Adaptive currently offers a clinical immunosequencing assay for monitoring minimal residual disease in multiple myeloma and acute lymphoblastic leukemia.

The agreement follows a number of other distribution deals Bioké has signed in recent months including ones with Omni Life Science, Syntec, and Namocell.

The high-throughput, scalable BD Cor system for infectious disease diagnostics is now available in Europe with the firm's BD Onclarity HPV assay. 

With RNA sequence data on thousands of individual lung cells, researchers fleshed out new and known cell clusters, before digging into cell state and cellular interaction changes in asthma.

The UK Competition and Markets Authority has announced concerns that the $1.2 billion merger will reduce competition for Illumina and could scrutinize it further.

The San Diego-based firm emerged from stealth mode with a plan to develop technologies to improve the quality and reduce the cost of genetic analysis.

The funding will support development of a test for the Zika virus using Ontera's silicon nanopore-based molecular diagnostics platform.

A UK court determined that Ariosa's licensee infringed upon at least one claim of Illumina's European patent 1 524 321 and upheld the patent's validity.

By comparing viruses in parts of China with or without endemic EBV-associated nasal cancers, researchers narrowed in on two viral variants associated with increased cancer risk.

A new analysis indicates that colorectal cancer metastases arise from a small number of cells before the primary tumor is large enough to be detected clinically.

A small but significant proportion of autism spectrum disorder cases — particularly those occurring in females — appeared to involve biallelic loss-of function or missense mutations.

Last week, GenomeWeb's readers were most interested in the Icahn School of Medicine's new clinical research arm that will help integrate AI into healthcare.

The acquisition will bring to Invitae single-molecule, cell-free DNA analysis technology and enable lower cost NIPS testing.

H.R. 3235, a long time priority for the National Society of Genetic Counselors, would allow CMS to reimburse genetic counselors for counseling Medicare beneficiaries.

Scientists from the UK and China discussed two new NIPTs that include single-gene disorders and a study to estimate disease recurrence risk in families.

The Patent Trial and Appeal Board has denied Foundation Medicine's request for Inter Partes review.

The researchers sequenced and analyzed the domesticated almond genome, uncovering why they are sweet, unlike bitter wild almonds.

Regeneron is covering the cost of the sequencing and genotyping, and both partners will have access to the data for research purposes.

The firm said that with the approval, the firm's liquid biopsy-based ExoDx Prostate IntelliScore (EPI) test is now available in every state.

The researchers are aiming to find molecular signatures in blood that identify previous exposures to materials associated with weapons of mass destruction.

Findings from a genome-wide association study suggest that fetal SNPs in SLIT2 and other genes may coincide with the risk of spontaneous preterm birth.

The deal makes Greenville, South Carolina-based Premier the only US lab to offer the genetic risk analysis assay from Spain's Patia.

Pages

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.